Marshak Joshua O, Dong Lichun, Koelle David M
Department of Medicine, University of Washington, 750 Republican Street, Room E651, Mail Stop 35806, Seattle, WA, 98195, USA.
Methods Mol Biol. 2014;1144:305-27. doi: 10.1007/978-1-4939-0428-0_21.
DNA vaccines have been licensed in veterinary medicine and have promise for humans. This format is relatively immunogenic in mice and guinea pigs, the two principle HSV-2 animal models, permitting rapid assessment of vectors, antigens, adjuvants, and delivery systems. Limitations include the relatively poor immunogenicity of naked DNA in humans and the profound differences in HSV-2 pathogenesis between host species. Herein, we detail lessons learned over the last few years investigating candidate DNA vaccines in the progesterone-primed female mouse vaginal model of HSV-2 infection as a guide to investigators in the field.
DNA疫苗已在兽医学中获得许可，并有望应用于人类。这种形式在小鼠和豚鼠这两种主要的HSV - 2动物模型中具有相对较强的免疫原性，能够快速评估载体、抗原、佐剂和递送系统。其局限性包括裸DNA在人类中的免疫原性相对较差，以及宿主物种之间HSV - 2发病机制存在巨大差异。在此，我们详细介绍过去几年在孕激素预处理的雌性小鼠阴道HSV - 2感染模型中研究候选DNA疫苗所获得的经验教训，为该领域的研究人员提供指导。
